# Biobeat > The first FDA\-cleared, cuffless 24\-hour ambulatory blood pressure monitoring system, enabling accurate hypertension diagnosis and chronic disease management through a patch\-worn wearable\. ## At a glance | Field | Value | | --- | --- | | Category | Data & Analytics | | Type | Solutions Provider | | Region | EMEA | | Headquarters | Petah Tikva, Israel (U.S. hub: Boca Raton, Florida) | | Founded | 2016 | | Stage | Growth | | Employees | 11-50 | | Funding | Series B | ## Overview Biobeat is an Israeli medical technology company that developed the first FDA-cleared, cuffless 24-hour ambulatory blood pressure monitoring (ABPM) system. Founded in 2016 by CEO Arik Ben Ishay and co-founders Johanan May and Israel Sarussi, the company's disposable chest patch device delivers continuous, non-invasive vital signs monitoring without the discomfort of traditional cuff-inflation cycles -- enabling uninterrupted sleep monitoring and eliminating white-coat syndrome artifacts. The platform has received multiple FDA clearances and CE marking, and is validated against gold-standard cuff-based monitoring with findings published in the American Journal of Hypertension. In December 2025, Biobeat closed a USD 50 million Series B round led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical, bringing total funding to approximately USD 71.8 million. The company established a U.S. hub in Boca Raton, Florida in 2024 and is actively expanding its U.S. commercial sales operation. Biobeat's remote patient monitoring platform connects directly to health insurers' value-based care programs, providing the clinical-grade ambulatory data required for hypertension diagnosis, chronic disease management, and reimbursable RPM services under Medicare and commercial payer guidelines. ## Products & services ### Chest Patch ABPM Monitor A disposable, short-term chest patch for 24-hour ambulatory blood pressure monitoring. FDA-cleared (K190792, K181006, K212153, K222010, K241066) and CE marked (2797). Validated against gold-standard cuff-based devices and published in peer-reviewed literature. **Key features:** - Cuffless, continuous blood pressure measurement over 24 hours - Eliminates white\-coat syndrome and masked hypertension artifacts - Uninterrupted nighttime monitoring without patient sleep disruption - Automatic clinical report generation for care providers - ACC/AHA guideline\-supported ambulatory monitoring methodology *Target users:* Cardiologists, hypertension specialists, primary care physicians, health systems ### Wrist Monitor A long-term wrist-worn device using PPG sensors for continuous measurement of 13 hemodynamic and vital parameters including blood pressure, SpO2, cardiac output, and respiratory rate. **Key features:** - Continuous multi\-parameter vital signs monitoring - Long\-term wear for chronic disease management - AI\-driven Early Warning Score \(EWS\) alerts - HIPAA and GDPR\-compliant cloud transmission *Target users:* Chronic disease management programs, hospital\-at\-home, post\-acute care ### Remote Patient Monitoring Platform Cloud-connected platform with mobile app integration, automated clinical report generation, and AI analytics. Supports reimbursable RPM workflows under CMS CPT codes (e.g., 99453, 99454). **Key features:** - Real\-time data transmission to mobile app and care team dashboard - Automated Early Warning Score with AI\-based clinical alerts - HIPAA and GDPR compliant - Integration with clinical workflows for hypertension diagnosis and chronic disease management *Target users:* Health systems, payers, employers running value\-based care programs ## Category & focus - Subcategories: Remote patient monitoring, wearable health tech, ambulatory blood pressure monitoring, vital signs monitoring - Insurance verticals: Health, Group Benefits - Target customers: Carriers, Employers, Consumers ## Notable customers - Hackensack Meridian Health \(HMH Emerge Program 2026 partner\) - Kestra Medical Technologies \(strategic partnership for wearable defibrillator patients\) ## Links - Website: - Directory profile: - Press/news: - Patient platform: --- *Last updated: 2026\-05\-11*